Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model?

The purpose of this study was to identify independent prognostic factors among preoperative imaging features in elderly glioblastoma patients and to evaluate whether these imaging features, in addition to clinical features, could enhance the predictive power of survival models. This retrospective study included 108 patients ≥65 years of age with newly diagnosed glioblastoma. Preoperative clinical features (age and KPS), postoperative clinical features (extent of surgery and postoperative treatment), and preoperative MRI features were assessed. Univariate and multivariate cox proportional hazards regression analyses for overall survival were performed. The integrated area under the receiver operating characteristic curve (iAUC) was calculated to evaluate the added value of imaging features in the survival model. External validation was independently performed with 40 additional patients ≥65 years of age with newly diagnosed glioblastoma. Eloquent area involvement, multifocality, and ependymal involvement on preoperative MRI as well as clinical features including age, preoperative KPS, extent of resection, and postoperative treatment were significantly associated with overall survival on univariate Cox regression. On multivariate analysis, extent of resection and ependymal involvement were independently associated with overall survival and preoperative KPS showed borderline significance. The model with both preoperative clinical and imaging features showed improved prediction of overall survival compared to the model with preoperative clinical features (iAUC, 0.670 vs. 0.600, difference 0.066, 95% CI 0.021–0.121). Analysis of the validation set yielded similar results (iAUC, 0.790 vs. 0.670, difference 0.123, 95% CI 0.021–0.260), externally validating this observation. Preoperative imaging features, including eloquent area involvement, multifocality, and ependymal involvement, in addition to clinical features, can improve the predictive power for overall survival in elderly glioblastoma patients.

[1]  A. Reiner,et al.  Glioblastoma in the elderly , 2009, Cancer.

[2]  S B Green,et al.  Patient age, histologic features, and length of survival in patients with glioblastoma multiforme , 1987, Cancer.

[3]  P. Black,et al.  Scale to predict survival after surgery for recurrent glioblastoma multiforme. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Menjot de Champfleur,et al.  Assessment and treatment relevance in elderly glioblastoma patients. , 2014, Neuro-oncology.

[5]  Susan M. Chang,et al.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy , 2008, Journal of Neuro-Oncology.

[6]  A. Friedman,et al.  Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. , 2016, Journal of neurosurgery.

[7]  S. Cha,et al.  Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. , 2013, Neuro-oncology.

[8]  Pascal O. Zinn,et al.  A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature , 2012, PloS one.

[9]  Oren Sagher,et al.  Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. , 2012, Journal of neurosurgery.

[10]  R. Fietkau,et al.  A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65 , 2017, American journal of clinical oncology.

[11]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[12]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[13]  J. García-Verdugo,et al.  Loss of p53 Induces Changes in the Behavior of Subventricular Zone Cells: Implication for the Genesis of Glial Tumors , 2006, The Journal of Neuroscience.

[14]  Mitchel S Berger,et al.  Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.

[15]  Jacob G. Scott,et al.  Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older , 2012, Cancer.

[16]  Scott VandenBerg,et al.  Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. , 2007, Neuro-oncology.

[17]  Raymond Sawaya,et al.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme , 2004, Journal of Neuro-Oncology.

[18]  X. Zhang,et al.  A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients , 2013, Journal of Neuro-Oncology.

[19]  William D. Dunn,et al.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.

[20]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[21]  Melissa Bondy,et al.  Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.

[22]  H. Seol,et al.  Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients , 2014, Acta Neurochirurgica.

[23]  Yuta Shibamoto,et al.  Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach , 2005, Journal of Neuro-Oncology.

[24]  P. Kehrli,et al.  Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy , 2013, Cancers.

[25]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[26]  Jay K. Nathan,et al.  Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma , 2013, Journal of Clinical Neuroscience.

[27]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[28]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[29]  H. Akaike.  A new look at the statistical model identification , 1974 .

[30]  Thomas Welzel,et al.  A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? , 2014, Radiation oncology.

[31]  D. Osoba,et al.  Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.

[32]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[33]  Samuel T Chao,et al.  Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. , 2011, Neuro-oncology.

[34]  Alfredo Quiñones-Hinojosa,et al.  A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. , 2010, Journal of neurosurgery.

[35]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[36]  H. Seol,et al.  A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. , 2013, Neuro-oncology.

[37]  Max Wintermark,et al.  Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. , 2015, Neuro-oncology.

[38]  Susan M. Chang,et al.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. , 2004, Neuro-oncology.

[39]  Paul S Mischel,et al.  MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.

[40]  Jordan M. Malof,et al.  Imaging descriptors improve the predictive power of survival models for glioblastoma patients. , 2013, Neuro-oncology.

[41]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[42]  J. Uhm,et al.  Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. , 2013, Journal of neurosurgery.